Abbott Laboratories 2014 Annual Report Download - page 32

Download and view the complete annual report

Please find page 32 of the 2014 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

30
ABBOTT 2014 ANNUAL REPORT
EMERGING
OPPORTUNITIES
TO MAKE A
DIFFERENCE
As economies around the world
expand, people have more
resources to devote to healthcare
and, increasingly, more choice
in how that money is spent.
When given that choice, they
look for the promise of quality
and ecacy that Abbott’s
pharmaceutical brands represent.
Over the next several years, our
focus on developing markets will
fuel our growth, as Abbott is well
aligned with the fundamentals
driving long-term growth for
healthcare in these regions.
2014 Business Review
ESTABLISHED
PHARMACEUTICALS
Abbott focuses on six core therapeutic
areas in which we have strong brands
and the ability to address significant
customer needs. These areas are:
• Gastroenterology
• Women’s Health
• Cardio-Metabolic
• Pain/Central Nervous System
• Respiratory Anti-Infectives
• Influenza Vaccine
2014 BUSINESS HIGHLIGHTS
• With the sale of our Developed Markets
pharmaceuticals business to Mylan, Abbott will focus
its energies in emerging markets
• Acquisition of CFR Pharmaceuticals makes Abbott
a top-ten company in Latin America
• Acquisition of Veropharm strengthens Abbott’s
commercial presence, R&D capability, manufacturing
capacity, and ability to serve patients in Russia